IONS

IONS

USD

Ionis Pharmaceuticals Inc. Common Stock

$73.550-0.240 (-0.325%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$73.790

High

$75.000

Low

$72.360

Volume

0.79M

Company Fundamentals

Market Cap

11.9B

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

2.47M

Exchange

NMS

Currency

USD

52-Week Range

Low $23.95Current $73.550High $76.78

Related News

Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $110

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals with a Buy and raises the price target from $100 to $110.

View more
HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $110
Analyst Upgrades

Piper Sandler Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $77

Piper Sandler analyst Allison Bratzel maintains Ionis Pharmaceuticals with a Overweight and raises the price target from $70 to $77.

View more
Piper Sandler Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $77
Analyst Upgrades

TD Cowen Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $99

TD Cowen analyst Yaron Werber maintains Ionis Pharmaceuticals with a Buy and raises the price target from $59 to $99.

View more
TD Cowen Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $99
Analyst Upgrades

Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $94

Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals with a Overweight and raises the price target from $90 to $94.

View more
Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $94
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $100

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals with a Buy and raises the price target from $95 to $100.

View more
HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $100
Analyst Upgrades

Barclays Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $95

Barclays analyst Gena Wang maintains Ionis Pharmaceuticals with a Overweight and raises the price target from $80 to $95.

Analyst Upgrades

RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $82

RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals with a Outperform and raises the price target from $80 to $82.